TARA

Healthcare Biotechnology

Protara Therapeutics, Inc.

$2.56

-0.07 -2.85% today

Price History

Not enough data

Key Stats

Market Cap

143.60M

Avg Volume

807,444

EPS

-$1.32

52W High

$7.82

52W Low

$2.53

Div. Yield

0.0%

Analyst Ratings

Buy

Str Buy

Buy

Hold

Sell

Str Sell

Valuation

Forward P/E

-1.51

P/B Ratio

0.94

EV/EBITDA

-0.20

Margins

Gross Margin 0.0%

Operating Margin 0.0%

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Return on Equity

(45.8%)

Return on Assets

(28.8%)

Liquidity & Leverage

Current Ratio

10.97

Quick Ratio

10.79

Debt / Equity

0.02

Total Cash

142.49M

Total Debt

2.75M

About

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.